Relmada Therapeutics Net Income
| RLMD Stock | USD 3.72 0.18 4.62% |
As of the 16th of February 2026, Relmada Therapeutics holds the Coefficient Of Variation of 1142.73, semi deviation of 4.0, and Risk Adjusted Performance of 0.079. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Relmada Therapeutics, as well as the relationship between them. Please check Relmada Therapeutics treynor ratio, as well as the relationship between the downside variance and kurtosis to decide if Relmada Therapeutics is priced some-what accurately, providing market reflects its current price of 3.72 per share. Given that Relmada Therapeutics has jensen alpha of 0.4079, we recommend you to check out Relmada Therapeutics's recent market performance to make sure the company can sustain itself at a future point.
Relmada Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Relmada Therapeutics' valuation are provided below:There are over one hundred nineteen available trending fundamental ratios for Relmada Therapeutics, which can be analyzed over time and compared to other ratios. Investors should ensure to check out all of Relmada Therapeutics' recent performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 33.4 M, whereas Enterprise Value is forecasted to decline to about 14.2 M. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -72 M | -68.4 M | |
| Net Loss | -72 M | -75.6 M | |
| Net Loss | -141.3 M | -148.4 M | |
| Net Loss | (3.05) | (3.20) |
Relmada | Net Income | Build AI portfolio with Relmada Stock |
Analyzing Relmada Therapeutics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Relmada Therapeutics's current valuation and future prospects.
Latest Relmada Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Relmada Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Relmada Therapeutics financial statement analysis. It represents the amount of money remaining after all of Relmada Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Relmada Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Relmada Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (79.98 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Relmada Net Income Regression Statistics
| Arithmetic Mean | (43,735,367) | |
| Coefficient Of Variation | (113.99) | |
| Mean Deviation | 42,639,635 | |
| Median | (20,803,596) | |
| Standard Deviation | 49,851,969 | |
| Sample Variance | 2485.2T | |
| Range | 157M | |
| R-Value | (0.76) | |
| Mean Square Error | 1117.5T | |
| R-Squared | 0.58 | |
| Significance | 0.0004 | |
| Slope | (7,508,220) | |
| Total Sum of Squares | 39763.5T |
Relmada Net Income History
Other Fundumenentals of Relmada Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Relmada Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Relmada Therapeutics is extremely important. It helps to project a fair market value of Relmada Stock properly, considering its historical fundamentals such as Net Income. Since Relmada Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Relmada Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Relmada Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Pharmaceuticals sector continue expanding? Could Relmada diversify its offerings? Factors like these will boost the valuation of Relmada Therapeutics. Anticipated expansion of Relmada directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Relmada Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Relmada Therapeutics's market price often diverges from its book value, the accounting figure shown on Relmada's balance sheet. Smart investors calculate Relmada Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Relmada Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Relmada Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Relmada Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Relmada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Relmada Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Relmada Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Relmada Therapeutics.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Relmada Therapeutics on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Relmada Therapeutics or generate 0.0% return on investment in Relmada Therapeutics over 90 days. Relmada Therapeutics is related to or competes with Acrivon Therapeutics, Pmv Pharmaceuticals, Immunic, Tscan Therapeutics, Vaxart, Lite Strategy, and Fortress Biotech. Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treat... More
Relmada Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Relmada Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Relmada Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.17 | |||
| Information Ratio | 0.0738 | |||
| Maximum Drawdown | 29.73 | |||
| Value At Risk | (8.60) | |||
| Potential Upside | 7.89 |
Relmada Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Relmada Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Relmada Therapeutics' standard deviation. In reality, there are many statistical measures that can use Relmada Therapeutics historical prices to predict the future Relmada Therapeutics' volatility.| Risk Adjusted Performance | 0.079 | |||
| Jensen Alpha | 0.4079 | |||
| Total Risk Alpha | 0.0577 | |||
| Sortino Ratio | 0.0907 | |||
| Treynor Ratio | 0.8767 |
Relmada Therapeutics February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.079 | |||
| Market Risk Adjusted Performance | 0.8867 | |||
| Mean Deviation | 3.94 | |||
| Semi Deviation | 4.0 | |||
| Downside Deviation | 4.17 | |||
| Coefficient Of Variation | 1142.73 | |||
| Standard Deviation | 5.12 | |||
| Variance | 26.19 | |||
| Information Ratio | 0.0738 | |||
| Jensen Alpha | 0.4079 | |||
| Total Risk Alpha | 0.0577 | |||
| Sortino Ratio | 0.0907 | |||
| Treynor Ratio | 0.8767 | |||
| Maximum Drawdown | 29.73 | |||
| Value At Risk | (8.60) | |||
| Potential Upside | 7.89 | |||
| Downside Variance | 17.36 | |||
| Semi Variance | 15.96 | |||
| Expected Short fall | (5.09) | |||
| Skewness | 0.6025 | |||
| Kurtosis | 1.58 |
Relmada Therapeutics Backtested Returns
Relmada Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of -0.0281, which implies the firm had a -0.0281 % return per unit of risk over the last 3 months. Relmada Therapeutics exposes twenty-nine different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Relmada Therapeutics' Semi Deviation of 4.0, risk adjusted performance of 0.079, and Coefficient Of Variation of 1142.73 to confirm the risk estimate we provide. The company holds a Beta of 0.5, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Relmada Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Relmada Therapeutics is expected to be smaller as well. At this point, Relmada Therapeutics has a negative expected return of -0.13%. Please make sure to check Relmada Therapeutics' treynor ratio, kurtosis, period momentum indicator, as well as the relationship between the downside variance and day median price , to decide if Relmada Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.12 |
Insignificant reverse predictability
Relmada Therapeutics has insignificant reverse predictability. Overlapping area represents the amount of predictability between Relmada Therapeutics time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Relmada Therapeutics price movement. The serial correlation of -0.12 indicates that less than 12.0% of current Relmada Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.12 | |
| Spearman Rank Test | -0.36 | |
| Residual Average | 0.0 | |
| Price Variance | 0.05 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Relmada Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Relmada Therapeutics reported net income of (79.98 Million). This is 123.43% lower than that of the Pharmaceuticals sector and 214.18% lower than that of the Health Care industry. The net income for all United States stocks is 114.01% higher than that of the company.
Relmada Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Relmada Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Relmada Therapeutics could also be used in its relative valuation, which is a method of valuing Relmada Therapeutics by comparing valuation metrics of similar companies.Relmada Therapeutics is currently under evaluation in net income category among its peers.
Relmada Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Relmada Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Relmada Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Relmada Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Relmada Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Relmada Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Relmada Therapeutics' value.| Shares | Renaissance Technologies Corp | 2025-06-30 | 150.1 K | Adar1 Capital Management Llc | 2025-06-30 | 130 K | Jane Street Group Llc | 2025-06-30 | 114.4 K | State Street Corp | 2025-06-30 | 106.7 K | We Are One Seven, Llc | 2025-06-30 | 100 K | Two Sigma Investments Llc | 2025-06-30 | 95.4 K | Susquehanna International Group, Llp | 2025-06-30 | 65.8 K | Northern Trust Corp | 2025-06-30 | 59.6 K | Lmr Partners Llp | 2025-06-30 | 55.1 K | Driehaus Capital Management Llc | 2025-06-30 | 740 K | Blackrock Inc | 2025-06-30 | 508 K |
Relmada Fundamentals
| Return On Equity | -1.97 | ||||
| Return On Asset | -1.02 | ||||
| Current Valuation | 258.91 M | ||||
| Shares Outstanding | 73.33 M | ||||
| Shares Owned By Insiders | 10.75 % | ||||
| Shares Owned By Institutions | 18.88 % | ||||
| Number Of Shares Shorted | 1.26 M | ||||
| Price To Earning | (1.27) X | ||||
| Price To Book | 28.82 X | ||||
| EBITDA | (83.89 M) | ||||
| Net Income | (79.98 M) | ||||
| Cash And Equivalents | 211.96 M | ||||
| Cash Per Share | 7.05 X | ||||
| Total Debt | 10.3 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 11.40 X | ||||
| Book Value Per Share | 0.28 X | ||||
| Cash Flow From Operations | (51.76 M) | ||||
| Short Ratio | 0.62 X | ||||
| Earnings Per Share | (1.78) X | ||||
| Target Price | 5.5 | ||||
| Number Of Employees | 17 | ||||
| Beta | 0.83 | ||||
| Market Capitalization | 330.73 M | ||||
| Total Asset | 45.82 M | ||||
| Retained Earnings | (640.88 M) | ||||
| Working Capital | 35.5 M | ||||
| Current Asset | 9.3 M | ||||
| Current Liabilities | 3.06 M | ||||
| Net Asset | 45.82 M |
About Relmada Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Relmada Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Relmada Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Relmada Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Relmada Therapeutics is a strong investment it is important to analyze Relmada Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Relmada Therapeutics' future performance. For an informed investment choice regarding Relmada Stock, refer to the following important reports:Check out For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Will Pharmaceuticals sector continue expanding? Could Relmada diversify its offerings? Factors like these will boost the valuation of Relmada Therapeutics. Anticipated expansion of Relmada directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Relmada Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Relmada Therapeutics's market price often diverges from its book value, the accounting figure shown on Relmada's balance sheet. Smart investors calculate Relmada Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Relmada Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Relmada Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Relmada Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Relmada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.